This article was originally published in The Rose Sheet
Second quarter sales were up 73% to $39.3 mil., company announces Nov. 14. Net income rose $4.4 mil., an 87% increase over the prior year. Earnings per share on a diluted basis increased 83% from $0.23 to $0.42. "The successful launch of GUESS? women's fragrance earlier this year continues to fuel our growth," CEO Ilia Lekach said, adding the firm is looking "forward to the launch of Perry Ellis 18 in 2006." Parlux also markets fragrances under the XOXO and Paris Hilton brands...
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.